

Sartorius Places 350 Million Euro Note Loan

Goettingen, May 24, 2017 – Sartorius, a leading international laboratory and pharmaceutical equipment provider, successfully placed a note loan with a volume of 350 million euros.

The note loan with maturity terms of 5, 7 and 10 years was arranged by Commerzbank and Landesbank Baden-Württemberg, and subscribed by national and international financial institutions, primarily savings banks and credit unions. The issue of the note loan was increased from 200 million euros to 350 million euros in view of the high demand by debt investors. The issue will be used for general corporate financing purposes and is in the context of the five acquisitions Sartorius made within the last 12 month.

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

A Profile of Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. More than 6,900 people work at the Group's 50 manufacturing and sales sites, serving customers around the globe.

Contact

Petra Kirchhoff

Vice President of Corporate Communications and Investor Relations

+49 (0)551.308.1686

petra.kirchhoff@sartorius.com